Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 1
- Registration Number
- NCT04700176
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 20
- Registration Number
- NCT04667663
- Locations
- 🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪Galway University Hospital, Galway, Ireland
🇮🇪Cork University Hospital, Cork, Ireland
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 96
- Registration Number
- NCT04661137
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 197
- Registration Number
- NCT04643002
- Locations
- 🇮🇱
Investigational Site Number : 3760002, Jerusalem, Israel
🇫🇷Investigational Site Number : 2500002, Lille, France
🇫🇷Investigational Site Number : 2500001, Nantes, France
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Natalie Callendar
- Registration Number
- NCT04584307
Pomalidomide Treatment in Patients With Kaposi Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT04577755
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT04508790
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 357
- Registration Number
- NCT04484623
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 586
- Registration Number
- NCT04458831
- Locations
- 🇺🇸
University of Arkansas Medical Sciences Site Number : 8400021, Little Rock, Arkansas, United States
🇺🇸St. Joseph Heritage Healthcare Site Number : 8400008, Fullerton, California, United States
🇺🇸University of California San Francisco (PARENT) Site Number : 8400009, San Francisco, California, United States
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 141
- Registration Number
- NCT04414475
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇬🇷Theageneion Cancer Hospital, Thessaloniki, Greece
🇮🇱Rabin Medical Center (Beilinson Hospital), Petah Tikva, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.